Estudo de braço único fase 2 | Futibatinibe para colangiocarcinoma intra-hepático rearranjado por FGFR2

Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma – New England Journal of Medicine (link para o resumo – $ para o texto completo)

Comentário: Futibatinib in Previously Treated Patients With Advanced FGFR2-Rearranged Intrahepatic Cholangiocarcinoma – ASCO Post

Comentário no Twitter

FGFR2 fusions or rearrangements occur in up to 14% of patients with intrahepatic cholangiocarcinoma. In a study, futibatinib, an FGFR inhibitor, induced responses (median, 9.7 months) in 42% of patients. https://t.co/FAXE2AnQ90 pic.twitter.com/9Fn9KxZxeg

— NEJM (@NEJM) January 19, 2023